Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Eli Lilly

Lilly’s Oral Drug Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

The finding sets up a near-term FDA filing under a priority review voucher.

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era

Rocket Lab Lands $190 Million Hypersonic Test Deal, Lifts Backlog Past $2 Billion

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

Oral GLP-1 Pill Orforglipron Delivers Phase III Weight Loss as Obesity Care Broadens Beyond Injections

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Trump Tariffs Drive Corporate Forecast Cuts and Supply Chain Shifts

Novo Nordisk Seeks FDA Approval as Eli Lilly's Weight-Loss Pill Advances

IMF Warns of Rising Risks as U.S. Tariff Actions Shake Global Markets

U.S.-Japan Trade Talks Show Progress as Global Markets React

FDA Ends Shortage of Eli Lilly’s Weight-Loss Drug, Restricts Copycat Versions

Eli Lilly Shares Plunge After Disappointing Q3 Earnings and Sales